PT  - JOURNAL ARTICLE
AU  - Goutham Pattabiraman
AU  - Ashlee J. Bell-Cohn
AU  - Stephen F. Murphy
AU  - Daniel J. Mazur
AU  - Anthony J. Schaeffer
AU  - Praveen Thumbikat
TI  - Mast cell function in prostate inflammation, fibrosis, and smooth muscle cell dysfunction
AID  - 10.1101/2021.03.23.436678
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.03.23.436678
4099  - http://biorxiv.org/content/early/2021/03/23/2021.03.23.436678.short
4100  - http://biorxiv.org/content/early/2021/03/23/2021.03.23.436678.full
AB  - Intraurethral inoculation of mice with uropathogenic E. coli (CP1) results in prostate inflammation, fibrosis, and urinary dysfunction, recapitulating some but not all of the pathognomonic clinical features associated with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). In both patients with LUTS and in CP1-infected mice, we observed increased numbers and activation of mast cells and elevated levels of prostate fibrosis. Therapeutic inhibition of mast cells and the histamine 1 receptor in the mouse model resulted in reduced mast cell activation in the prostate and significant alleviation of urinary dysfunction. Treated mice showed reduced prostate fibrosis, less infiltration of immune cells, and decreased inflammation. In addition, as opposed to symptomatic CP1-infected mice, treated mice showed reduced myosin light chain (MLC)-2 phosphorylation, a marker of prostate smooth muscle contraction. These results show that mast cells play a critical role in the pathophysiology of urinary dysfunction and may be an important therapeutic target for men with BPH/LUTS.NEW AND NOTEWORTHY LUTS-associated BPH is derived from a combination of immune activation, extracellular matrix remodeling, hyperplasia, and smooth muscle cell contraction in prostates of men. Using a mouse model, we describe the importance of mast cells in regulating these multiple facets involved in the pathophysiology of LUTS. Mast cell inhibition alleviates both pathology and urinary dysfunction in this model suggesting the potential for mast cell inhibition as a therapeutic that prevents and reverses pathology and associated symptomology.Competing Interest StatementThe authors have declared no competing interest.